TriSalus Life Sciences, Inc. (NASDAQ:TLSIW – Get Free Report)’s stock price traded up 15.2% during trading on Thursday . The company traded as high as $1.67 and last traded at $1.67. 225 shares changed hands during trading, a decline of 95% from the average session volume of 4,498 shares. The stock had previously closed at $1.45.
TriSalus Life Sciences Stock Performance
The stock has a 50-day moving average price of $1.19 and a 200 day moving average price of $1.22.
TriSalus Life Sciences Company Profile
TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.
Further Reading
- Five stocks we like better than TriSalus Life Sciences
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- What is a Stock Market Index and How Do You Use Them?
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
- How to Calculate Inflation Rate
- Tesla: 2 Reasons to Buy, 1 Reason to Run
Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
